ArticleScientific reports2025
Impact of particle size and surface modifications on the neurotoxic potential of copper oxide nanoparticles.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Comprehensive Review on Copper Oxide Nanoparticles: Physicochemical Parameters, Pharmacological Potential and Pathophysiological Effects.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Copper oxide (CuO) nanoparticles (NPs) have widespread applications in electronics, energy storage, and healthcare domains owing to their high surface-to-volume ratio, catalytic activity, and anti-bacterial and anti-microbial properties. However, the health hazard of direct CuO exposure to humans has raised safety concerns. CuO NPs can cross the blood-brain barrier, access the central nervous system, and trigger neurotoxicity. Previous studies have investigated the neurotoxicity of CuO NPs. However, the effects of different sizes and comparable size NPs with and without surface coating have not been previously reported. In this study, two differentially sized NPs (CuO-25 and CuO-48 NPs) and one polyvinylpyrrolidone-coated NP (CuO-P NPs; 46 nm) were synthesized and characterized. The neurotoxic potential of these NPs was examined in vitro using PC-12 cells. CuO NPs significantly decreased cell viability at concentrations of ≥ 1 μg/mL by inducing oxidative and nitrosative stress in a time-dependent and concentration-dependent manner. Additionally, CuO NPs altered mitochondrial membrane potential, upregulated Il6 and Tnf levels, induced apoptosis by upregulating Casp3 activity, and inhibited acetylcholinesterase activity. Furthermore, CuO NPs upregulated the expression of Maoa and Snca, which are associated with dopamine metabolism and the pathogenesis of neurodegenerative disorders. The three NPs exerted differential effects. The cytotoxic effects of CuO-25 NPs were higher than those of CuO-48 NPs. Additionally, the cytotoxic effects of coated NPs (CuO-P) were lower than those of uncoated NPs. Cu
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.